Congressional Accountability Tracker

[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H.R. 1492 Introduced in House (IH)]

<DOC>

119th CONGRESS
  1st Session
                                H. R. 1492

     To amend title XI of the Social Security Act to equalize the 
negotiation period between small-molecule and biologic candidates under 
                  the Drug Price Negotiation Program.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                           February 21, 2025

 Mr. Murphy (for himself, Mr. Davis of North Carolina, and Mr. Hudson) 
 introduced the following bill; which was referred to the Committee on 
   Energy and Commerce, and in addition to the Committee on Ways and 
 Means, for a period to be subsequently determined by the Speaker, in 
   each case for consideration of such provisions as fall within the 
                jurisdiction of the committee concerned

_______________________________________________________________________

                                 A BILL

 
     To amend title XI of the Social Security Act to equalize the 
negotiation period between small-molecule and biologic candidates under 
                  the Drug Price Negotiation Program.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. EQUALIZING THE NEGOTIATION PERIOD BETWEEN SMALL-MOLECULE AND 
              BIOLOGIC CANDIDATES UNDER THE DRUG PRICE NEGOTIATION 
              PROGRAM.

    (a) In General.--Section 1192(e)(1)(A)(ii) of the Social Security 
Act (42 U.S.C. 1320f-1(e)(1)(A)(ii)) is amended by striking ``7 years'' 
and inserting ``11 years''.
    (b) Effective Date.--The amendment made by subsection (a) shall 
take effect as if included in the enactment of Public Law 117-169.
                                 <all>
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.

Full Text
